Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Reports Increase in Q3 Revenue, R&D Spending, Net Income

NEW YORK, Oct. 28 - Qiagen today reported strong third-quarter revenue growth, an in increase in R&D spending, and a slight jump in net income.

 

For the period ended Sept. 30, Qiagen said net sales were $76.9 million compared with $63.3 million during the same quarter one year ago.

 

R&D spending in the third quarter increased to $7.3 million from $6.1 million year over year.

 

Net income for the quarter increased $7.3 million, or $.05 per share, from $6.2 million, or $.04 in the year-ago quarter, the company said.

 

Qiagen said it has roughly $51.8 million in cash and cash equivalents as of Sept. 30.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.